IMMU.ST

Healthcare Biotechnology

Mendus AB (publ)

SEK 6.06

-0.14 -2.26% today

Price History

Not enough data

Key Stats

Market Cap

384.71M

Avg Volume

23,814

EPS

-SEK 1.79

52W High

SEK 8.49

52W Low

SEK 3.86

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-12.37

P/B Ratio

0.71

EV/EBITDA

-3.84

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(17.9%)

Return on Assets

(9.7%)

Liquidity & Leverage

Current Ratio

1.14

Quick Ratio

1.06

Debt / Equity

0.03

Total Cash

59.88M

Total Debt

17.93M

About

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.